If you are on testosterone, got put on an estrogen blocker for a high number, and now your drive is gone and your midsection is growing, there is a reason.
A man starts testosterone. Estradiol rises on the labs. Someone reaches for an aromatase inhibitor (an estrogen blocker) almost automatically. Weeks later, libido is flat, erections feel weaker, and the midsection softens even when the testosterone number still looks "good" on paper.
That is not random bad luck. Part of testosterone's message is delivered as estradiol. Brain, bones, fat tissue, and sexual function all read that signal. Crash the conversion without a clear clinical reason, and you can remove a signal those tissues were using.
For the broader question of whether men on TRT should block estrogen by default, see Should You Block Estrogen on TRT? What the Research Shows.
Some testosterone becomes estradiol on purpose
Most of a man's circulating estradiol, roughly 80%, is made from testosterone by aromatase. Raise testosterone and estradiol often rises with it. That rise is expected physiology, not proof that something is automatically broken.
Estradiol in men is not "contamination." At physiologic levels it helps with sexual desire and erectile function, fat distribution, bone health, and other systems your body actually uses. The cultural reflex that treats any male estradiol as "bad estrogen" skips that biology.
When a blocker is added purely to chase a lower number, you are changing a hormone signal that sexual function and body composition partly depend on.
What the New England Journal study actually showed
This used to be hard to separate cleanly, because testosterone and estradiol normally move together. A landmark New England Journal of Medicine trial solved that in healthy men ages 20 to 50. Researchers suppressed both hormones with goserelin, then added testosterone back at different doses for 16 weeks, with half the men also given full-dose anastrozole to block conversion to estradiol (Finkelstein et al., 2013).
That was near-complete estrogen blockade, more extreme than most real-world use, which is exactly why the labs matter. The design still lets researchers ask which outcomes tracked with low testosterone versus low estradiol.
What they found was specific. Loss of lean mass, muscle size, and strength tracked mainly with testosterone deficiency. Estrogen deficiency primarily accounted for the fat gain. Sexual desire and erectile function declined when either hormone was deficient. In that model, both testosterone and estradiol regulate sexual function. Blocking estrogen while chasing a testosterone number does not protect sexual function.
A follow-up from the same group looked at bone with the same design. Estrogen deficiency drove spine bone loss regardless of testosterone dose (QCT spine BMD fell across testosterone doses when aromatization was blocked). Bone turnover markers reflected both hormones. In that 2016 work, estradiol levels above about 10 pg/mL generally protected bone; levels must decline substantially to impact the skeleton (Finkelstein et al., 2016). You will not feel bone density change the week the blocker starts. Libido and midsection changes are often what men notice first.
Sensitive estradiol plus SHBG, not a casual immunoassay alone
Before anyone adds a blocker for a "high estrogen" number, I want the right test in the conversation.
The assay that matters for many of these decisions is a sensitive estradiol method (often liquid chromatography-mass spectrometry, LC-MS/MS), not a standard immunoassay. In men, immunoassays can read falsely high through cross-reactivity. That inflated number is often what started the blocker in the first place. If a result is going to justify starting, stopping, or changing a blocker, assay quality matters.
SHBG (sex hormone-binding globulin) belongs in the same picture. It binds testosterone and estradiol and changes how much free hormone is available. A single total estradiol number without context is a weak reason to start a standing blocker.
Confirm the clinical reason before the blocker
Not every man on testosterone needs an aromatase inhibitor. Anastrozole is FDA-approved for breast cancer in postmenopausal women. Use in men is off-label. Off-label can be appropriate in selected cases. It still deserves a documented reason, informed consent, and follow-up, not a reflex start on day one of testosterone.
Legitimate reasons to evaluate and sometimes treat exist. Documented high estradiol with matching symptoms, breast tenderness or gynecomastia, significant water retention tied to a clear elevation, and similar pictures can justify a careful conversation. Those are not the same as a prophylactic blocker added the day testosterone starts because a forum said estrogen is the enemy.
Before a blocker goes on the plan, I want three questions answered honestly:
- Was the estradiol measured with a sensitive assay, and does SHBG help interpret it?
- Do the patient's symptoms actually match a high-estradiol picture, or do they look more like low estradiol (flat drive, weaker erections, midsection gaining) after a blocker was already started? Joint discomfort sometimes gets discussed as a softer low-estradiol clue, mostly from aromatase-inhibitor data in women, so I treat it as supportive context rather than a stand-alone reason.
- Is there a clearer fix upstream (dose, injection frequency, body fat, alcohol, other meds) before we suppress conversion?
If drive disappeared and the midsection grew after the blocker started, the useful move is often to reassess the blocker and the labs with the clinician managing your care, not to keep stacking more testosterone on top of a missing estradiol signal.
After a blocker change: recheck, do not guess
If a blocker is started, stopped, or adjusted, recheck sensitive estradiol, SHBG, and the symptoms that drove the decision. A rough clinical timeframe is often several weeks for drive and related symptoms, and longer (often a few months) before body-composition shifts are clear enough to judge. Exact timing and lab intervals belong with the clinician who knows your history. No dosing protocol belongs in a blog post.
A familiar clinic pattern
A man in his mid-40s came in already on testosterone elsewhere, already on a standing estrogen blocker for one elevated estradiol printout. His total testosterone looked fine. His drive was gone. His midsection had softened over a few months. Nobody had drawn a sensitive estradiol after the blocker started.
When we checked, estradiol was pushed well below a physiologic male range. The complaints tracked with that, not with "not enough testosterone." We confirmed the labs, matched the symptoms, and his managing clinician adjusted the plan so estradiol could return toward a normal male range. Drive often shifted over the following weeks. Body composition, when it shifts, more often takes months.
That is one composite pattern, not a guarantee for every reader. It is why "confirm number and match symptoms" belongs before the bottle.
Part 2 tease: steadier testosterone, fewer estradiol spikes
One reason estradiol can look "spiky" on testosterone therapy is the delivery pattern itself. Large, infrequent testosterone peaks can drive larger swings in conversion. Steadier testosterone exposure (dose, route, and interval chosen with a clinician who knows your labs) often means fewer sharp estradiol spikes for the same average testosterone exposure.
That is clinical physiology and a Part 2 conversation: how dosing rhythm changes the estradiol ride without treating every rise as an automatic blocker.
What I want you to take away
If you are on testosterone plus an estrogen blocker and your drive is gone while your midsection is growing, do not assume you simply need more testosterone.
Ask whether part of the message you needed was estradiol. Ask whether the blocker was added for a documented, symptomatic reason or for a cultural reflex. Ask whether the estradiol assay was sensitive enough to trust, and whether SHBG was in the picture. The New England Journal work showed that estrogen deficiency primarily accounted for increases in body fat, and that both testosterone and estradiol regulate sexual function in that controlled model.
Education only. Individual decisions stay with a licensed clinician who knows your history and labs.
Where to take this next
If you are already a patient at a 4Ever Young clinic, take this information to your clinic team. Talk with the clinical staff who already know you and your history. I support that care.
If you are not located near a 4Ever Young clinic and would like a conversation with me virtually, email me at drwilcox@precisionhormoneconsulting.com or DM @wellnessdoc_4everyoung on Instagram.
Darrell Wilcox, MD | @wellnessdoc_4everyoung on Instagram
Wellness Doc ยท 4Ever Young
Sources
Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. PMID: 24024838.
Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016;126(3):1114-1125. PMID: 26901812.
This content is for educational purposes only and does not constitute medical advice. Hormone and lab decisions deserve individualized evaluation with a licensed clinician who knows your history. No outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas, Arizona, Colorado, Oregon, and Florida.
